1 At the same time, there are no fewer than 6 lawsuits currently pending against the IRA, filed by Merck, the US Chamber of ...

If you’re on the fence about investing in Merck ... 0% net profit margin. Year-over-year quarterly sales growth most recently was 7.2%. Analysts expect adjusted earnings to reach $8.061 per share for ...

In the same breath, Herbosa reiterated the government’s intention to launch the Bakuna Eskwela or school-based vaccination programs, including the introduction of the HPV vaccine for girls 14 ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Health Canada authorized Novavax’s updated COVID-19 vaccine that protects against currently circulating variants of the virus on Thursday. The protein-based vaccine, called Nuvaxovid ...

DAKAR, Senegal — The global vaccine alliance Gavi will buy 500,000 doses of mpox vaccine to battle outbreaks of the disease in African countries, the organization said on Wednesday. The vaccine ...

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

The government has been evaluating two new COVID-19 vaccines targeting the JN.1 strain and appears to chosen one of them. Australians could soon have access to at least one new COVID-19 vaccine ...

Mpox vaccines have been administered in Africa for the first time, with several hundred high-risk individuals vaccinated in Rwanda, the African Union's disease control centre said Thursday.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.01 per share and revenue of $64.14 billion, indicating changes of +430.46% and +6. ... moved 0.01% lower. Merck ...

The US Centers for Disease Control and Prevention (CDC) recommends vaccination with two doses of the Jynneos mpox vaccine for people in the US at high risk of catching the virus. In terms of bite ...